drugset / Trial / NCT00627692

Evaluation of the Safety and Tolerability of Prucalopride in Constipated Elderly Subjects Living in a Nursing Facility

NCT00627692

Phase 2 Completed 100 enrolled Movetis
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether prucalopride is safe and effective in the treatment of constipation in elderly subjects living in a nursing facility. Hypothesis: Prucalopride up to a dose of 4 mg once daily is safe and well tolerated in in elderly subjects living in a nursing facility.

Timeline

Start
1999-02
Primary completion
2000-05
Completion
2000-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prucalopride Small molecule 0.5 mg Oral
Comparator Prucalopride Small molecule 1 mg Oral
Comparator Prucalopride Small molecule 2 mg Oral
Comparator Prucalopride Small molecule 4 mg Oral

Indications